UNTOLD: Survey on Unmet Needs After Ovarian Cancer
Official title: UNderstanding The Experience of Ovarian Cancer Life After Diagnosis (UNTOLD) Study
Run by Masonic Cancer Center, University of Minnesota · NCT07070726 · Data updated 2026-11-12
This project will ask people who have had ovarian cancer to complete a one-time survey (and some a follow-up interview) to learn about ongoing concerns and unmet needs.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 2000 (estimated) |
| Sponsor | Masonic Cancer Center, University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | July 10, 2025 |
| Main results expected | June 30, 2027 |
| Study ends | January 1, 2029 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT07070726 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who can read and write English are the intended participants.
✕Probably not a fit
People who cannot read or write English or who do not have ovarian, primary peritoneal, or fallopian tube cancer are not eligible and would not directly benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The UNTOLD study uses a mixed-methods approach to measure ongoing concerns and unmet needs among ovarian cancer survivors. Participants will complete a one-time survey about quality of life and survivorship experiences, and up to 40 respondents will be invited for a follow-up interview to explore issues in more depth. Recruitment combines population-based sampling through the California Cancer Registry with outreach via ovarian cancer advocacy groups to enhance representativeness. The study is coordinated by the Masonic Cancer Center at the University of Minnesota and requires the ability to read and write English.
Why it matters
Potential benefit: If successful, the findings could help healthcare providers and advocacy groups create better survivorship resources and support tailored to ovarian cancer survivors' real needs.
How similar studies have gone: Similar survivorship surveys and mixed-methods research have previously identified actionable unmet needs, so this approach is established in the field.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to read and write in English * Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube) Exclusion Criteria: \-
Where it's running
-
Masonic Cancer Center
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Study coordinator: Rachel Vogel, PhD
- Email: isak0023@umn.edu
- Phone: 612-624-6928
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.